Insider Purchases: Inside the Buy
Tag: Small Cap Stocks
Badger Meter (BMI) Stock Analysis 2026: Insider Buys After 24% Crash 💧📉
Badger Meter just took a 24% hit—but the CEO is buying the dip. With strong long-term water infrastructure trends and improved valuation, is BMI a hidden opportunity or just treading water?
$500K Insider Bet at 52-Week Lows: Is Shoe Carnival (SCVL) a Hidden Gem? 👟
Shoe Carnival (SCVL) is trading near lows with a $500K insider buy, high short interest, and ultra-cheap valuation. Is this a hidden value play—or a classic trap? 👟
🛢️ HMH Stock: Insiders Buy Millions After IPO Dip — Opportunity or Trap? 📉📈
HMH just IPO’d… and insiders are already buying millions. From strong margins to a pivot into mining and geothermal, here’s why this overlooked energy stock is getting attention.
Phreesia (PHR): Profitable… Then Crushed — Why Insiders Are Loading Up
Phreesia just hit profitability—and got punished for it. With insiders loading up and institutions fully committed, is this a classic overreaction or a value trap? Let’s decode the dip.
IPX Stock: America’s Titanium Comeback—or a Costly Experiment? 🦾
IperionX is betting on a U.S. titanium comeback. With government backing and disruptive tech, the upside is huge—but so are the risks.
1 comment
|
AbCellera (ABCL) Stock Analysis: 7 Triggers for a Biotech Short Squeeze or Long-Term Multibagger?
Down 95%, heavily shorted, yet sitting on $700M in liquidity and insider conviction — AbCellera (ABCL) may be biotech’s ultimate asymmetric bet.
Can XOMA Become Royalty? The CEO, BVF Partners, and Morgan Stanley Think So!
XOMA Royalty doesn’t run clinical trials—it collects royalties. With a $2.5M CEO insider buy, heavyweight institutional backing, and improving cash flow, this biotech quiet achiever may be turning into something… royal.